BiotechTube

Fluticasone + Fluticason

Pre-clinicalCompleted
0 watching 0 views this week💤 Quiet
23
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Allergy

Conditions

Allergy

Trial Timeline

Nov 1, 2010 → Jul 1, 2011

NCT ID
NCT01240889

About Fluticasone + Fluticason

Fluticasone + Fluticason is a pre-clinical stage product being developed by Roche for Allergy. The current trial status is completed. This product is registered under clinical trial identifier NCT01240889. Target conditions include Allergy.

Hype Score Breakdown

Clinical
5
Activity
2
Company
10
Novelty
2
Community
1

Clinical Trials (1)

NCT IDPhaseStatus
NCT01240889Pre-clinicalCompleted

Competing Products

20 competing products in Allergy

See all competitors
ProductCompanyStageHype Score
ASP0892 Intradermal + ASP0892 Intramuscular + Placebo Intradermal + Placebo IntramuscularAstellas PharmaPhase 1
33
ASP0892 + PlaceboAstellas PharmaPhase 1
33
Cetirizine 10mg + Cetirizine 10 mg + Cetirizine 10 mgJohnson & JohnsonPhase 1
33
Cetirizine + CetirizineJohnson & JohnsonPhase 1
33
AcalabrutinibAstraZenecaPhase 2
52
OmalizumabNovartisPhase 1
33
ligelizumab + PlaceboNovartisPhase 3
77
remibrutinib + placeboNovartisPhase 2
52
Placebo + XolairNovartisApproved
85
QGE031 + PlaceboNovartisPhase 2
52
Ligelizumab 120 mg + Ligelizumab 240 mgNovartisPhase 3
77
Omalizumab + Placebo for Omalizumab + Multi-Allergen Oral Immunotherapy + Placebo for Multi-Allergen Oral ImmunotherapyNovartisPhase 3
77
QGE031 + PlaceboNovartisPhase 1
33
OmalizumabNovartisApproved
85
Omalizumab InjectionRocheApproved
85
Dupilumab + Placebo matching dupilumab + AR101SanofiPhase 2
51
Fexofenadine HCISanofiApproved
84
DupilumabSanofiPhase 2
51
Glucopyranosyl Lipid A (GLA) + Sublingual Immuno Therapy (SLIT) Peanut Extract (PE) + Placebo for GLA + Placebo for SLIT PESanofiPhase 1
32
DupilumabRegeneron PharmaceuticalsPre-clinical
22

Other Products from Roche

EmicizumabApproved
85
rituximab + methotrexate + methylprednisolone + acetaminophen + antihistamineApproved
85
RituximabApproved
85
mycophenolate mofetil [CellCept]Approved
85
saquinavir/ritonavir + atazanavir/ritonavirApproved
85